Zobrazeno 1 - 6
of 6
pro vyhledávání: '"I. P. Naya"'
Autor:
F. Maltais, I. P. Naya, C. F. Vogelmeier, I. H. Boucot, P. W. Jones, L. Bjermer, L. Tombs, C. Compton, D. A. Lipson, E. M. Kerwin
Publikováno v:
Respiratory Research, Vol 21, Iss 1, Pp 1-12 (2020)
Abstract Background Short-acting β2-agonist (SABA) bronchodilators help alleviate symptoms in chronic obstructive pulmonary disease (COPD) and may be a useful marker of symptom severity. This analysis investigated whether SABA use impacts treatment
Externí odkaz:
https://doaj.org/article/99e7710a1bbd4fefbaecd5c24df2ee4f
Autor:
M. T. Driessen, J. Whalen, B. Seewoodharry Buguth, L. A. Vallejo-Aparicio, I. P. Naya, Y. Asukai, B. Alcázar-Navarrete, M. Miravitlles, F. García-Río, N. A. Risebrough
Publikováno v:
Respiratory Research, Vol 19, Iss 1, Pp 1-13 (2018)
Abstract Background A head-to-head study demonstrated the superiority of once-daily umeclidinium bromide/vilanterol (UMEC/VI) 62.5/25 mcg on trough forced expiratory volume in 1 s (FEV1) versus once-daily tiotropium/olodaterol (TIO/OLO) 5/5 mcg in sy
Externí odkaz:
https://doaj.org/article/27dcccc5f4aa4c789151dca4288b6268
Autor:
M. T. Driessen, J. Whalen, B. Seewoodharry Buguth, L. A. Vallejo-Aparicio, I. P. Naya, Y. Asukai, B. Alcázar-Navarrete, M. Miravitlles, F. García-Río, N. A. Risebrough
Publikováno v:
Respiratory Research, Vol 20, Iss 1, Pp 1-1 (2019)
Following publication of the original article [1], we have been notified of the below corrections to the 5th paragraph in the Discussion section.
Externí odkaz:
https://doaj.org/article/df0b71c8ab6a488db37b204dcccf6fa5
Autor:
F. Maltais, I. P. Naya, C. F. Vogelmeier, I. H. Boucot, P. W. Jones, L. Bjermer, L. Tombs, C. Compton, D. A. Lipson, E. M. Kerwin
Additional file 1. Distribution of baseline SABA use (puffs/day)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4a4a1bb36a3f61f0c0b726ed4684a53d
Autor:
F. Maltais, I. P. Naya, C. F. Vogelmeier, I. H. Boucot, P. W. Jones, L. Bjermer, L. Tombs, C. Compton, D. A. Lipson, E. M. Kerwin
Additional file 2. Study treatment withdrawal
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::32e918f9f7fef7c6e55c26975783b272
Autor:
M T, Driessen, J, Whalen, B Seewoodharry, Buguth, L A, Vallejo-Aparicio, I P, Naya, Y, Asukai, B, Alcázar-Navarrete, M, Miravitlles, F, García-Río, N A, Risebrough
Publikováno v:
Respiratory Research, Vol 20, Iss 1, Pp 1-1 (2019)
Respiratory Research
Respiratory Research
Background A head-to-head study demonstrated the superiority of once-daily umeclidinium bromide/vilanterol (UMEC/VI) 62.5/25 mcg on trough forced expiratory volume in 1 s (FEV1) versus once-daily tiotropium/olodaterol (TIO/OLO) 5/5 mcg in symptomatic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::87ddec4517bf08f7f1db64ce4fee69e9
https://hdl.handle.net/10668/13475
https://hdl.handle.net/10668/13475